Ruth Coleman Vindicated

Publikováno v: The Compass, 1936 Dec 01. 18(3), 14-14.

Externí odkaz: https://www.jstor.org/stable/23705691

Bubble-PAPR: a phase 1 clinical evaluation of the comfort and perception of a prototype powered air-purifying respirator for use by healthcare workers in an acute hospital setting

Autor: Brendan A McGrath, James Lynch, Peter G Alexander, Glen Cooper, Ruth Coleman, Clifford L Shelton, Angela Gardner

Publikováno v: BMJ Open, Vol 13, Iss 5 (2023)

Objectives We aimed to design and produce a low-cost, ergonomic, hood-integrated powered air-purifying respirator (Bubble-PAPR) for pandemic healthcare use, offering optimal and equitable protection to all staff. We hypothesised that participants wou

Externí odkaz: https://doaj.org/article/be7f3e29d63648bbb4255d62d8e1079b

Examining the role of moral, emotional, behavioural, and personality factors in predicting online shaming.

Autor: Shannon Raine Muir, Lynne Diane Roberts, Lorraine Sheridan, Amy Ruth Coleman

Publikováno v: PLoS ONE, Vol 18, Iss 3, p e0279750 (2023)

Online shaming, where people engage in social policing by shaming perceived transgressions via the internet, is a widespread global phenomenon. Despite its negative consequences, scarce research has been conducted and existing knowledge is largely an

Externí odkaz: https://doaj.org/article/5f24b2c782a84639961ea2cdc741d84e

Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes

Autor: Paul Harrison, M. Angelyn Bethel, Irene Kennedy, Robert Dinsdale, Ruth Coleman, Rury R. Holman

Publikováno v: Platelets, Vol 30, Iss 4, Pp 521-529 (2019)

The antiplatelet efficacy of aspirin (ASA) is reduced in type 2 diabetes (T2D). As the best ex vivo method of measuring ASA efficacy remains uncertain, we compared nine platelet function tests to assess responsiveness to three ASA dosing regimens in

Externí odkaz: https://doaj.org/article/470be060714648b3ac5f6116cf1404cb

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin:The Randomized, Controlled EMPA-VISION Trial

Autor: Moritz J. Hundertmark, Amanda Adler, Charalambos Antoniades, Ruth Coleman, Julian L. Griffin, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Daniel Massey, Jack J.J.J. Miller, Joanne E. Milton, Shveta Monga, Ferenc E. Mózes, Areesha Nazeer, Betty Raman, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovič, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer

Publikováno v: Hundertmark, M J, Adler, A, Antoniades, C, Coleman, R, Griffin, J L, Holman, R R, Lamlum, H, Lee, J, Massey, D, Miller, J J J J, Milton, J E, Monga, S, Mózes, F E, Nazeer, A, Raman, B, Rider, O, Rodgers, C T, Valkovič, L, Wicks, E, Mahmod, M & Neubauer, S 2023, ' Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin : The Randomized, Controlled EMPA-VISION Trial ', Circulation, vol. 147, no. 22, pp. 1654-1669 . https://doi.org/10.1161/CIRCULATIONAHA.122.062021

BACKGROUND: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6991061491711a9400f62c93ebf46fa4
https://pure.au.dk/portal/da/publications/assessment-of-cardiac-energy-metabolism-function-and-physiology-in-patients-with-heart-failure-taking-empagliflozin(06821eb7-dc78-4441-a6b4-a23ac2bcfaf6).html